Abbott Lingo
Abbott
What it is
Abbott's consumer "biowearable" — a wellness glucose sensor built on the older FreeStyle Libre 2, deliberately narrowed to a 55–200 mg/dL range with no alarms, no trend arrows and no interoperability. Explicitly not a diabetes device and not for insulin users; we cover it to map the OTC/wellness CGM edge of the landscape.
Editorial review: .
Most recent recorded citation date: 2025-12-08. Only explicit date metadata is included; an undated citation may be newer. This does not mean every claim was reviewed on that date.
Trial status, labels and access can change between reviews. How we review the evidence · How to read the evidence
Evidence behind this assessment
Key evidence notes. Study results, product eligibility and access answer different questions.
- Who was studied?
- Study populations and analysis groups vary. Product age limits alone do not describe who was studied.
- Benefit or performance
- Accuracy: Per-range MARD was 9.9% under 70 mg/dL, 9.7% at 70–180, and 8.1% above 180, based on the FreeStyle Libre 2 pivotal-study data — but the device only reports 55–200 mg/dL, so it never shows true severe lows or highs.[1]
- Important harms and treatment burden
- Read the safety discussion and original sources. A missing summary does not establish safety.
- Approval and country access
- Country-specific approval and access are not summarized in this record.Approval, trial recruitment, local supply and funding are separate. Check the cited label or access source.
- Follow-up and remaining uncertainty
- Read the full discussion and original sources for follow-up duration and study limitations.
This record cites company or conference reports. Those sources may describe interim findings; their source type is shown in the source list.
Editorial score: calculation and evidence
A weighted editorial judgment on a 0–100 scale, not a probability of success or a measured treatment effect. Higher criterion scores mean more favorable assessments.
Default calculation: 70 × 20 + 60 × 15 + 5 × 15 + 78 × 10 + 95 × 10 + 3 × 10 + 80 × 10 + 0 × 5 + 40 × 5 = 5135; divide by total weight 100. Unrounded weighted result: 51.35.
Per-range MARD was 9.9% under 70 mg/dL, 9.7% at 70–180, and 8.1% above 180, based on the FreeStyle Libre 2 pivotal-study data — but the device only reports 55–200 mg/dL, so it never shows true severe lows or highs.[1]
Same interstitial glucose sensing as the Libre platform, so physiological lag is inherent; the app receives streamed values, so trends are at least granular.[1]
Closed by design — "Device features to manage diabetes: None." No insulin pens, no AID systems, no DIY loop, no receiver; pairs only with the Lingo coaching app on the user's own phone. Useless for T1D dosing.[1]
Up to 14-day wear, but reliability is mediocre for a CGM — only 77.1% of sensors lasted to the final day in testing (roughly 1 in 5 ended early).[1]
No glucose alarms of any kind and no trend arrows — the FDA comparison lists alarms as a feature of the Libre 2 predicate that Lingo removes. It cannot warn you of a low. A hard dealbreaker for insulin-treated T1D.[1]
No prescription needed; tiered consumer pricing that varies with the number of sensors.[3]
The full picture
Lingo is Abbott's consumer "biowearable" — a glucose sensor sold for general health and wellness, not for managing diabetes. It is a small round sensor worn on the back of the upper arm that reads glucose in the fluid just under your skin and sends readings to the Lingo coaching app on your phone.1 We cover it to map the wellness edge of the CGM landscape; almost everything about it makes it less suitable for type 1 than a prescription sensor, not more.
What it is built from. Under the hood Lingo's hardware and clearance are based on the older FreeStyle Libre 2 (predicate K222447).1 The FDA cleared it in the US on 10 June 2024 as an over-the-counter iCGM for people 18 and older who are not on insulin; in the UK it was announced in January 2024, sold as a non-medical wellness device.25 Abbott is explicit that Lingo is "not intended for diagnosis of diseases, including diabetes."3
Accuracy. Abbott re-analysed the Libre 2 pivotal study to support Lingo; per glucose range the reported MARD (mean absolute relative difference — lower is better) was 9.9% below 70 mg/dL, 9.7% at 70–180, and 8.1% above 180.1 The catch that matters most for T1D: Lingo only reports glucose from 55 to 200 mg/dL — a deliberately truncated range. It will not show you a true severe low or a high; the Libre 2 it is based on reads 40–400 mg/dL.1
Wear and calibration. Up to 14 days per sensor, factory-calibrated with no fingersticks.1 Reliability is unimpressive: in testing only 77.1% of sensors lasted to the final day — roughly one in five ended early.1
Alerts — the dealbreaker. Lingo has no glucose alarms at all, and no trend arrows. The FDA's own comparison table lists alarms, trend arrows and interoperability as features of the Libre 2 predicate that Lingo strips out ("Device features to manage diabetes: None").1 It cannot warn you of a low — disqualifying for anyone on insulin.
What it connects to. Nothing useful for T1D. The system "is not intended to be used in conjunction with insulin devices such as insulin pens and Automated Insulin Dosing (AID) systems," and it pairs with the Lingo coaching app rather than a receiver or pump.1 The app launched on iOS and added Android in December 2025.6 Instead of dosing tools it offers a "Lingo Count" spike metric, meal/exercise logging, and habit challenges.3
Ketones. None — glucose only.1
Who it's for. Adults 18+ not on insulin who want to see how food, exercise and sleep move their glucose — wellness users, not people with type 1.2 It is explicitly not for insulin users, dialysis, or critical illness, and vitamin C intake above 1000 mg/day can falsely raise readings.1
Access & cost. No prescription needed. The US and UK offer tiered plans priced by the number of sensors, from a single two-week sensor up to a multi-sensor program.345 US pricing was listed at $49 for one 14-day sensor, $89 for two, or $249 for six.4
What's coming. Abbott's direction for Lingo has been consumer reach, not diabetes capability — wider retail availability and the move to Android in late 2025.6 For T1D, the relevant Abbott devices are the prescription FreeStyle Libre sensors and their AID ecosystem, tracked separately on this site — not Lingo.
Sources
- [1]510(k) K233655 — Lingo Glucose System, Substantial Equivalence Decision Summary · Regulatory decision · 2024-05-29 — Primary FDA review document. Confirms OTC iCGM, 18+/not-on-insulin indication, FreeStyle Libre 2 (K222447) predicate, factory calibration, 14-day wear, 55–200 mg/dL reportable range, no alarms/trend arrows/interoperability, per-range and per-wear-period MARD tables, and the 77.1% sensor-survival figure.
U.S. Food & Drug Administration. 510(k) K233655 — Lingo Glucose System, Substantial Equivalence Decision Summary (29 May 2024).
- [2]Abbott Receives U.S. FDA Clearance for Two New Over-the-Counter Continuous Glucose Monitoring Systems · Manufacturer · 2024-06-10 — Abbott press release announcing the 10 June 2024 OTC clearance of Lingo (wellness) and Libre Rio (type 2). Confirms 18+/not-on-insulin and the wellness-vs-diabetes split between the two products.
Abbott. Abbott Receives U.S. FDA Clearance for Two New Over-the-Counter Continuous Glucose Monitoring Systems. PR Newswire (10 June 2024).
- [3]Abbott's Lingo Continuous Glucose Monitor for Health and Wellness Now Available in the U.S. · Manufacturer · 2024-09-05 — US availability (5 Sept 2024) and three consumer plan tiers; reiterates "not intended for diagnosis of diseases, including diabetes."
Abbott. Abbott's Lingo Continuous Glucose Monitor for Health and Wellness Now Available in the U.S. Abbott Newsroom (5 Sept 2024).
- [4]Abbott debuts Lingo over-the-counter CGM in the US · Science journalism · 2024-09-06 — MedTech Dive — confirms US launch, tiered consumer pricing, and wellness/non-insulin positioning.
Reuter E. Abbott debuts Lingo over-the-counter CGM in the US. MedTech Dive (6 Sept 2024).
- [5]Lingo by Abbott — UK consumer glucose biosensor · Manufacturer · 2024-01-09 — UK launch (9 Jan 2024) as a non-medical wellness biowearable, sold as consumer wellness packs; explicitly "not intended for medical use… or monitoring of diseases, including diabetes."
Abbott. Lingo by Abbott — UK.
- [6]Abbott expands Lingo OTC CGM to Android devices · Science journalism · 2025-12-08 — Lingo was iOS-only at launch; the app reached Android (Google Play) on 8 Dec 2025, after Amazon/Walmart retail expansion earlier in 2025.
Hale C. Abbott expands Lingo OTC CGM to Android devices. Drug Delivery Business News (8 Dec 2025).